Bluetooth Special Interest Group enables wireless glucose monitor development
KIRKLAND, Wash. — The Bluetooth Special Interest Group recently adopted the continuousglucose monitoring profile, developed by the Medical Device Working Group, to standardize data collection, measurement and delivery for Bluetooth Smart glucose monitors. Bluetooth Smart brings convenience to medical devices while empowering patients and medical providers alike with accurate pictures of activity, health — and in this case — blood sugar levels, the company said.
“Bluetooth wireless technology, led by Bluetooth Smart, makes it possible for developers and OEMS to build wireless wearable devices – watches, glasses, fitness trackers – that work reliably with the products consumers already own,” said Errett Kroeter, senior marketing director for the Bluetooth SIG. “We are seeing this same market enablement start to play out in the medical industry, thanks to the flexibility, interoperability and global accessibility of Bluetooth Smart. The CGM profile is just the tip of the iceberg.”
Accurate testing and monitoring is an essential element in managing and treating, not only diabetes, but most medical issues. Bluetooth Smart enabled sensors can give patients and medical providers a more accurate, full-picture look at the body’s response to a prescribed treatment plan, delivering information in real time. This potential will lead to connectivity growth in the medical industry in the coming years, Bluetooth SIG noted.
“Devices in health and wellness monitoring applications are projected to grow from 2.9 million in 2013 to 17.1 million in 2018,” said Lee Ratliff, principal analyst, connectivity and IoT for IHS Technology. “Of total health and wellness devices, 851,000 were Bluetooth Smart enabled in 2013; this figure is projected to reach 13.2 million annually by 2018.”
Low-dose aspirin’s risk-benefit ratio may not add up for younger women
LONDON — The pros of giving healthy women regular low dose aspirin to stave off such serious illness as cancer and heart disease are outweighed by the cons, suggests a large study published online last week in the journal Heart.
But the balance begins to shift with increasing age, and limiting this form of primary prevention to women ages 65 years and older proved better than either not taking aspirin at all or treating women from the age of 45 years and older.
Reseachers based their findings on almost 30,000 healthy women, who were at least 45 years old and taking part in the Women's Health Study. Participants were randomly assigned to take either 100 mg of aspirin or a placebo every other day, to see whether aspirin curbed their risk of heart disease, stroke and cancer.
Compared with placebo, regular aspirin was linked to a lower risk of heart disease, stroke, bowel cancer, and in some women, other cancers, but only marginally so.
And this slight health gain was trumped by the prevalence of internal gastrointestinal bleeding, which affected two thirds of the women taking the non-steroidal anti-inflammatory drug.
The risk of gastrointestinal bleeding rose with age, but so too did the drug's impact on lowering the risk of bowel cancer and cardiovascular disease, with the balance appearing to tip in favor of the drug for women ages 65 years and older.
The researchers calculated that older than 15 years, 29 older-than-65 year olds would need to be treated with aspirin to prevent one case of cancer or heart disease/stroke.
NBTY names Coca Cola executive president of NBTY Americas and CEO United States Nutrition
RONKONKOMA, N.Y. — NBTY on Monday announced the appointment of Brian Wynne to the role of president of NBTY Americas, and CEO of its U.S. subsidiary – United States Nutrition. In this role he will have general management responsibility and P&L accountability for NBTY's wholesale brands in North America and South America.
"Brian is an experienced senior executive with an outstanding track record for driving and delivering positive business results and delivering shareholder value in a large, fast paced environment," said Steve Cahillane, NBTY president and CEO. "He is a highly collaborative leader and his addition to our leadership team will effectively round out our sales and marketing functions and will have a profound and positive impact on our customers and our consumers."
Wynne is a 25-year consumer packaged goods industry veteran who comes to NBTY from The Coca-Cola Company, where he most recently served as SVP strategy, franchise relations and transformation for Coca-Cola North America Group. Prior to this role, Wynne served as president of the Coca-Cola Company's North American Still Beverages Unit.
Wynne begins his new role on Jan. 1, 2015 and will be based in Ronkonkoma, N.Y. He succeeds Glenn Schneider, who stepped down in October, from his position as president global wholesale.
Wynne, age 50, earned a bachelor of arts degree in communications from Villanova University. He also has management certificates from Kellogg School of Management, Northwestern University; Columbia University; and the University of Michigan.
Loading Post Please Wait...